Caribou Biosciences, Inc.
CRBU
$0.79
$0.03264.30%
| Weiss Ratings | CRBU - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | CRBU - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | CRBU - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.91 | |||
| Price History | CRBU - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -15.88% | |||
| 30-Day Total Return | -36.29% | |||
| 60-Day Total Return | -51.83% | |||
| 90-Day Total Return | -60.89% | |||
| Year to Date Total Return | -52.98% | |||
| 1-Year Total Return | -81.88% | |||
| 2-Year Total Return | -83.68% | |||
| 3-Year Total Return | -90.44% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -83.50% | |||
| 52-Week Low % Change | 14.76% | |||
| Price | CRBU - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $4.59 | |||
| 52-Week Low Price | $0.66 | |||
| 52-Week Low Price (Date) | Apr 07, 2025 | |||
| 52-Week High Price (Date) | Apr 09, 2024 | |||
| Valuation | CRBU - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 70.44M | |||
| Enterprise Value | -152.46M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.65 | |||
| Earnings Per Share Growth | 14.03% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 6.91 | |||
| Price/Book (Q) | 0.28 | |||
| Enterprise Value/Revenue (TTM) | -15.25 | |||
| Price | $0.79 | |||
| Enterprise Value/EBITDA (TTM) | 0.97 | |||
| Enterprise Value/EBIT | 0.94 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | CRBU - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 91.16M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | CRBU - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 510 982 6030 | |||
| Address | 2929 7th Street Berkeley, CA 94710 | |||
| Website | cariboubio.com | |||
| Country | United States | |||
| Year Founded | 2011 | |||
| Profitability | CRBU - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -1,616.12% | |||
| Profit Margin | -1,491.94% | |||
| Management Effectiveness | CRBU - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -27.08% | |||
| Return on Equity | -- | |||
| Income Statement | CRBU - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 9.99M | |||
| Total Revenue (TTM) | 9.99M | |||
| Revenue Per Share | $0.11 | |||
| Gross Profit (TTM) | -118.96M | |||
| EBITDA (TTM) | -157.59M | |||
| EBIT (TTM) | -161.52M | |||
| Net Income (TTM) | -149.11M | |||
| Net Income Avl. to Common (TTM) | -149.11M | |||
| Total Revenue Growth (Q YOY) | -41.62% | |||
| Earnings Growth (Q YOY) | -2.85% | |||
| EPS Diluted (TTM) | -1.65 | |||
| EPS Diluted Growth (Q YOY) | 0.23% | |||
| Balance Sheet | CRBU - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 209.54M | |||
| Cash Per Share (Q) | $2.30 | |||
| Total Current Assets (Q) | 219.38M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 252.95M | |||
| Current Ratio (Q) | 7.157 | |||
| Book Value Per Share (Q) | $2.74 | |||
| Total Assets (Q) | 313.31M | |||
| Total Current Liabilities (Q) | 30.65M | |||
| Total Debt (Q) | 26.49M | |||
| Total Liabilities (Q) | 60.36M | |||
| Total Common Equity (Q) | 252.95M | |||
| Cash Flow | CRBU - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 86.61M | |||
| Cash from Financing (TTM) | 16.72M | |||
| Net Change in Cash (TTM) | -34.87M | |||
| Levered Free Cash Flow (TTM) | -84.52M | |||
| Cash from Operations (TTM) | -138.20M | |||
